Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis | |
Song, Yuqin1; Gao, Quanli2; Zhang, Huilai3; Fan, Lei4; Zhou, Jianfeng5; Zou, Dehui6,7; Li, Wei8; Yang, Haiyan9; Liu, Ting10; Wang, Quanshun11 | |
刊名 | CLINICAL CANCER RESEARCH |
2022-03-15 | |
卷号 | 28 |
ISSN号 | 1078-0432 |
DOI | 10.1158/1078-0432.CCR-21-2023 |
通讯作者 | Zhu, Jun(zhu-jun2017@outlook.com) |
英文摘要 | Purpose: Tislelizumab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody specifically designed to minimize binding to Fry receptors (Fc gamma R). Patients and Methods: Here, we present the extended 3-year follow-up of a phase II study of tislelizumab in 70 patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who failed or were ineligible for autologous stem cell transplantation. Results: With a median follow-up of 33.8 months, the overall response rate by the independent review committee was 87.1%, and the complete response (CR) rate was 67.1%. Responses were durable as shown by a median duration of response of 31.3 months, and median progression-free survival (PPS) of 31.5 months. The 3-year PFS and overall survival rates were 40.8% and 84.8%, respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 97.1% of patients; the grade >= 3 TRAE rate was low (31.4%), and only 8.6% of patients experienced adverse events leading to treatment discontinuation. Correlative biomarker analysis showed that Fc gamma RI-expressing macrophages had no observed impact on either the CR rate or PFS achieved with tislelizumab, which may be potentially related to its engineered Fc region. Conclusions: With extended follow-up, tislelizumab yielded long-term benefits and demonstrated a favorable safety profile for patients with relapsed/refractory cHL. |
资助项目 | BeiGene (Beijing) Co., Ltd., Beijing, China ; BeiGene USA, Inc., San Mateo, CA ; Ify Sargeant, Kathryn Quinn ; Maxine Skipp on the behalf of Twist Medical |
WOS关键词 | REED-STERNBERG CELLS ; B-CELL ; SINGLE-ARM ; BRENTUXIMAB VEDOTIN ; ANALYSIS REVEALS ; PHASE-II ; EXPRESSION ; TRANSPLANTATION ; MULTICOHORT ; MULTICENTER |
WOS研究方向 | Oncology |
语种 | 英语 |
出版者 | AMER ASSOC CANCER RESEARCH |
WOS记录号 | WOS:000772209800001 |
资助机构 | BeiGene (Beijing) Co., Ltd., Beijing, China ; BeiGene USA, Inc., San Mateo, CA ; Ify Sargeant, Kathryn Quinn ; Maxine Skipp on the behalf of Twist Medical |
内容类型 | 期刊论文 |
源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/128213] |
专题 | 中国科学院合肥物质科学研究院 |
通讯作者 | Zhu, Jun |
作者单位 | 1.Peking Univ Canc Hosp & Inst, Beijing Canc Hosp, Dept Lymphoma, Beijing, Peoples R China 2.Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Immunotherapy, Zhengzhou, Peoples R China 3.Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China 4.Nanjing Med Univ, Jiangsu Prov Hosp, Collaborat Innovat Ctr Canc Personalized Med, Dept HematoL,Affiliated Hosp 1, Nanjing, Peoples R China 5.Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China 6.Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Inst Hematol, Tianjin, Peoples R China 7.Chinese Acad Med Sci & Peking Union Med Coll, Coll Med, Blood Dis Hosp, Tianjin, Peoples R China 8.Jilin Univ, Hosp 1, Dept Hematol, Canc Ctr, Changchun, Peoples R China 9.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Lymphoma, Hangzhou, Peoples R China 10.Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China |
推荐引用方式 GB/T 7714 | Song, Yuqin,Gao, Quanli,Zhang, Huilai,et al. Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis[J]. CLINICAL CANCER RESEARCH,2022,28. |
APA | Song, Yuqin.,Gao, Quanli.,Zhang, Huilai.,Fan, Lei.,Zhou, Jianfeng.,...&Zhu, Jun.(2022).Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis.CLINICAL CANCER RESEARCH,28. |
MLA | Song, Yuqin,et al."Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis".CLINICAL CANCER RESEARCH 28(2022). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论